Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 4:45 PM
Ignite Modification Date:
2025-12-24 @ 4:45 PM
NCT ID:
NCT01082250
Brief Summary:
A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
Detailed Description:
12.5% Drugload 3X40mg vs. 25% Drugload 1X120mg
Study:
NCT01082250
Study Brief:
Protocol Section:
NCT01082250